Moderna sues Pfizer and BioNTech for patent infringement involving COVID-19 vaccines

Moderna sued Pfizer and BioNTech “for infringing patents central to (its) mRNA technology platform,” the company said in a news release Friday.

“Moderna believes that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna’s foundational mRNA technology. This groundbreaking technology was critical to the development of Moderna’s own mRNA COVID-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna’s permission, to make Comirnaty,” the news release said.

Moderna said it believes Pfizer copied two key features of its patented technologies that is says are “critical to the success of mRNA vaccines.”

“We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic,” said Moderna Chief Executive Officer Stéphane Bancel.

“This foundational platform, which we began building in 2010, along with our patented work on coronaviruses in 2015 and 2016, enabled us to produce a safe and highly effective COVID-19 vaccine in record time after the pandemic struck. As we work to combat health challenges moving forward, Moderna is using our mRNA technology platform to develop medicines that could treat and prevent infectious diseases like influenza and HIV, as well as autoimmune and cardiovascular diseases and rare forms of cancer.”

Both companies made tens of billions of dollars selling their coronavirus vaccines.

Colleen Kelleher

Colleen Kelleher is an award-winning journalist who has been with WTOP since 1996. Kelleher joined WTOP as the afternoon radio writer and night and weekend editor and made the move to WTOP.com in 2001. Now she works early mornings as the site's Senior Digital Editor.

This content was republished with permission from CNN.

More from WTOP

Log in to your WTOP account for notifications and alerts customized for you.

Sign up